Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma.

about

Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments

P2860

Q26852206-5C2D77D5-B70C-4B70-A9AA-62F3743E916C

P2860

Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma.

Item

http://www.wikidata.org/entity/Q36741917

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Repeated favorable responses t ...... advanced lung adenocarcinoma.

@ast

Repeated favorable responses t ...... advanced lung adenocarcinoma.

@en

type

Item

label

Repeated favorable responses t ...... advanced lung adenocarcinoma.

@ast

Repeated favorable responses t ...... advanced lung adenocarcinoma.

@en

prefLabel

Repeated favorable responses t ...... advanced lung adenocarcinoma.

@ast

Repeated favorable responses t ...... advanced lung adenocarcinoma.

@en

P1476

Repeated favorable responses t ...... advanced lung adenocarcinoma.

@en

P2093

Eun-Young Kim

http://www.w3.org/2001/XMLSchema#string

Hee-Jung Ban

http://www.w3.org/2001/XMLSchema#string

In-Jae Oh

http://www.w3.org/2001/XMLSchema#string

Kyu-Sik Kim

http://www.w3.org/2001/XMLSchema#string

Sung-Chul Lim

http://www.w3.org/2001/XMLSchema#string

Yong-Soo Kwon

http://www.w3.org/2001/XMLSchema#string

Yoon-Hee Kim

http://www.w3.org/2001/XMLSchema#string

Young-Chul Kim

http://www.w3.org/2001/XMLSchema#string

Yu-Il Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Clinical benefit of readministration of gefitinib for initial gefitinib-responders with non-small cell lung cancer.

Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor

Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Clinical responses to EGFR-tyrosine kinase inhibitor retreatment in non-small cell lung cancer patients who benefited from prior effective gefitinib therapy: a retrospective analysis.

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway.

New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer.

PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib.

Predictors of the response to gefitinib in refractory non-small cell lung cancer.

P304

129-133

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

case report

P356

10.4046/TRD.2013.74.3.129

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-03-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236196137

http://www.w3.org/2001/XMLSchema#string

P698

23579627

http://www.w3.org/2001/XMLSchema#string

P932

3617133

http://www.w3.org/2001/XMLSchema#string

Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma.

about

P2860

P2860

Repeated favorable responses to epidermal growth factor receptor-tyrosine kinase inhibitors in a case of advanced lung adenocarcinoma.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P5875

P698

P932